Atreca, a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the completion of its Series B funding round with a total investment of $35 million. The financing was co-led by the new investor Wellington Management Company LLP and the large US-based healthcare-focused fund, which participated as an existing Atreca investor. Additional participation included new investor Cormorant Asset Management, based in Boston, as well as new and existing investors.
Funding proceeds will be used to accelerate and broaden Atreca’s discovery and development of antibody-based therapy that initiates, shapes and drives anti-tumor immune response in cancer patients, as enabled by proprietary Immune Repertoire Capture® (IRCTM) technology. Atreca’s technology provides unbiased and virtually error-free antibody and T cell receptor (TCR) sequences of active human immune responses at high throughput from single B and T cells, enabling the identification, generation and analysis of functional human antibodies and TCRs directly from such responses.
“We are very pleased with the continued support of our existing investors and the commitment of our new high-caliber investors,” said Tito A. Serafini, Ph’s D. D. , President of Atreca, Chief Executive Officer, and Co-Founder “We continue to build a foundation for long-term growth with their participation. This funding enables us to accelerate the acquisition of central immune response data for cancer immunotherapy and to expand and advance our pipeline of novel antibody therapy based on these data. “To date, Atreca has built a library of more than 400 patient-derived antibodies that bind non-autologous tumor tissue as the foundation for its pipeline and anticipates nominating a clinical candidate in its lead oncology program by the end of the year.
“Atreca’s novel and differentiated approach has the potential to address broad, compelling unmet needs in diverse immuno-oncology applications, a global market that is expected to exceed $100 billion in five years,” said Brian Atwood, Chairman of Atreca. “We are thrilled by the continued momentum of the Company and the top-tier financing syndicate participating in the Series B round “That’s right.
Atreca is a privately held biotechnological company developing novel human immune response therapy, including effective anti-cancer immune responses. We can measure and analyze the structure of clinically relevant immune responses to identify antibodies, T cell receptors and targets that are key to successful treatment outcomes. Atreca’s proprietary immune repertoire Capture technology profiles a patient’s immune response at a very high throughput level, essentially without bias or error, allowing the identification and generation of functional human antibodies and TCRs without prior antigen knowledge. The Company is developing a pipeline of candidates to engage the human immune response in oncology and other indications, thus leading to better therapeutic outcomes. For more information about Atreca, please visit www. Atreca: Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Atreca/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at firstname.lastname@example.org